Aimmune Therapeutics Inc

Aimmune Therapeutics — Investor Presentation (June 2019)

36 slides from Aimmune Therapeutics's investor presentation, Jun 18, 2019

  1. Slide 1: June 2019 Corporate Presentation

    June 2019 Corporate Presentation Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, clinical development plans, anticipated milestones, product candidate benefits, potential market size, product adoption

  3. Slide 3: Aimmune Positioned for Success

    Aimmune Positioned for Success 1 Potential to launch first ever FDA approved product to treat peanut allergy 2 Analyst consensus for peak sales of AR101 for peanut allergy > $1 Bn Compelling efficacy profile in 656 patients à both clinical benefit and significant QoL improvement Safety and tolerabil

  4. Slide 4: Approved Food Allergy Treatments are a Major Unmet Need

    Approved Food Allergy Treatments are a Major Unmet Need Over 15 million people in the U.S. have food allergies1-3 Every 3 minutes, a food allergy reaction sends someone in the U.S. to the ER4 ~$4 billion per year in direct medical expenses in the U.S.5 50% increase in the prevalence of food allergy

  5. Slide 5: Aspiring to become the global leader in food allergy therapies

    At Aimmune we aspire to become the global leader in developing curative therapies and solutions for patients with food allergies

  6. Slide 6: Building the Leading Food Allergy Company Focused on Near- and Long-Term Growth

    Building the Leading Food Allergy Company Focused on Near- and Long-Term Growth Deliver AR101 Expand CODIT Advance Adjunctive Biologics 1 2 3 Secure approval and launch by 1Q2020 in US and 3Q2020 in EU Expand AR101 reach and impact through geography and age expansion Expand applications; Egg program

  7. Slide 7: We Aim to Provide the Bridge to Confidence

    Accidental exposures happen Constant risk and worry Risk of death We Aim to Provide the Bridge to Confidence Regular interaction with allergist during desensitization process offers reassurance Desensitization and Immunomodulation Protection from life-threatening reactions Daily confirmation Peace o

  8. Slide 8: Oral Pathway Provides Robust Desensitization and Patient Convenience

    Oral Pathway Provides Robust Desensitization and Patient Convenience Goal of oral immunotherapy is to minimize the body’s reaction to trigger foods High levels of desensitization can be achieved with oral immunotherapy1 Convenient, once-daily, oral dose taken with food doesn’t stigmatize patients Ai

  9. Slide 9: CODIT Food Allergy Treatment Pipeline

    Regulatory Filing Pre-IND Clinic Ready Phase 2 Phase 3 Next Milestones CODIT™ Food Allergy Treatment Pipeline AR101 (BTD in patients age 4-17) AR101 + Adjunctive Dupilumab AR101 Pediatric Study (patients age 1-3) Product optimization AR201 Formulation Results 2020 Results TBD File IND Initiate mid-2

  10. Slide 10: Peanut Allergy is One of the Most Common Food Allergies

    Peanut Allergy is One of the Most Common Food Allergies 1 Aimmune market research 2Gupta RS, Lau CH,, Sita EE, el al. Factors associated with reported food allergy tolerance among US children. Ann Allergy Asthma Immunol. 2013;111(3):194–198.e4 3 Gupta RS, Warren CM, Smith BM, et al. The Public Healt

  11. Slide 11: Peanuts are Everywhere: Avoidance is a Challenging Strategy

    Peanut allergens can be hard to spot Median accidental exposure that causes a reaction is ~ 1/2 a peanut2 One accident can be fatal Peanuts are Everywhere: Avoidance is a Challenging Strategy 1 of 4 peanut-allergic patients visit the ER every year1 Fear, anxiety and confusion set in immediately afte

  12. Slide 12: Biologic Mechanics of Oral Immunotherapy

    Biologic Mechanics of Oral Immunotherapy 300 mg Dose Escalation Continued Immunomodulation psIgE is expected to decrease over time Therapeutic Dose High IgE Phase psIgE elevated Hold at 300 mg Immunomodulation 6 months 12 months 3–5 years Baseline Peanut-Specific IgE IgE, immunoglobulin E. *Data wit

  13. Slide 13: Multiple Clinical Trials Add to Body of Evidence to Support Benefit of AR101

    Multiple Clinical Trials Add to Body of Evidence to Support Benefit of AR101: PALISADE, RAMSES, ARTEMIS, ARC004 and ARC011

  14. Slide 14: PALISADE Met Primary and Key Secondary Efficacy Endpoints

    PALISADE Met Primary and Key Secondary Efficacy Endpoints: Intent-to-Treat Analysis Patients Ages 4-17 Who Tolerated Each Dose Level at Exit DBPCFC *p<0.00001 for Treatment Difference >15% DBPCFC: Double-Blind, Placebo-Controlled Food Challenge Jones S, et al. AAAAI 2018 (full presentation available

  15. Slide 15: ARTEMIS Efficacy Comparable to That Seen in PALISADE

    ARTEMIS Efficacy Comparable to That Seen in PALISADE ITT Population (n=175); Efficacy assessed by an independent blinded assessor at exit DBPCFC ∆ between groups = 56.0% (95% CI: 44.1%, 65.2%) p<0.0001 Placebo (n=43) AR101 (n=132) Primary Endpoint Key Secondary Endpoints *p<0.0001 for H0:Treatment D

  16. Slide 16: Longitudinal Change in Highest Tolerated Dose

    Longitudinal Change in Highest Tolerated Dose ITT Analysis: Median Amount of Peanut Protein Tolerated in Entry and Exit DBPCFCs 10 mg 10 mg 1000 mg 30 mg Jones S, et al. AAAAI 2018 (full presentation available at aimmune.com) ITT: Intent-to-Treat Population, 4-17 age group DBPCFCs: Double-Blind, Pla

  17. Slide 17: AR101 Reduced the Incidence and Severity of Allergic Reactions

    In Phase 3 PALISADE Study, AR101 Reduced the Incidence and Severity of Allergic Reactions Vickery BP et al. N Engl J Med. 2018;379:1991-2001 *Double-blind, placebo-controlled food challenge None Mild Moderate Severe 3 mg 10 mg 600 mg 30 mg 100 mg 300 mg 1,000 mg 3 mg 13 mg 1,043 mg 43 mg 143 mg 443

  18. Slide 18: Efficacy of Continued Therapeutic Dose (300 mg/day)

    100.0 98.1 86.5 89.4 64.4 79.8 49.0 Efficacy of Continued Therapeutic Dose (300 mg/day) Tolerated Doses, ARC004 Completer Population Exit DBPCFC (n=104)* *Only the PALISADE and ARC004 results of the 104 subjects completing ARC004 cohort 1 were compared. DBPCFC, double-blind, placebo-controlled food

  19. Slide 19: Baseline vs Exit Maximum Tolerated Dose

    Baseline vs Exit Maximum Tolerated Dose (MTD)* MTD at EXIT Food Challenge (mg) MTD at ENTRY Food Challenge (mg) ≤ 3 mg (N=128) 10 mg (N=104) 30 mg (N=140) 1000 600 300 100 30 10 3 1 Discontinued 40% 62% 47% 11% 9% 1% 1% 22% 10% 1% 2% 19% 9% 2% 2% 1% 16% 18% 27% * AR101 patients in PALISADE

  20. Slide 20: Accidental Peanut Exposures in PALISADE

    Accidental Peanut Exposures in PALISADE Dose Escalation Patients with ≥ 1 of the following AR101 N = 366 Placebo N = 123 Accidental exposure 5.7% 8.1% Accidental exposure resulting in AE 5.7% 7.3% Accidental exposure resulting in AE requiring treatment 5.1% 6.5% *Excludes the initial escalation peri

  21. Slide 21: Frequency of Most Common AEs Declined During Fixed Dosing

    AR101 Placebo Frequency of Most Common AEs Declined During Fixed Dosing* *Most Common AEs with ≥ 5 Percentage Points Higher Frequency vs Placebo. Source: Integrated Safety Summary: controlled population from studies ARC003 and ARC007. Patients (%)

  22. Slide 22: Related Treatment Emergent Adverse Events Decrease Over Time

    Related Treatment Emergent Adverse Events Decrease Over Time Overall there are 0.07 severe events per year of AR101 exposure * TEAE: treatment emergent adverse events; IDE: Initial Dose Escalation; TD: 300 mg daily therapeutic dose; SYE: subject years of exposure Source: Integrated Safety Summary: i

  23. Slide 23: 75% of Systemic Allergic Reactions Occur Within Two Hours of Dosing

    75% of Systemic Allergic Reactions Occur Within Two Hours of Dosing * Source: Integrated Safety Summary: controlled population from studies ARC003 and ARC007

  24. Slide 24: Time to Onset of Systemic Allergic Reactions from Last Dose of AR101

    Time to Onset of Systemic Allergic Reactions from Last Dose of AR101* * Source: Integrated Safety Summary: includes 812 subjects dosed with AR101 in Phase 3 clinical trials as of December 15, 2018

  25. Slide 25: AR101 Profile Changes Over Time

    AR101 Profile Changes Over Time Ratio of psIgE to psIgG4 continues to decrease Peanut tolerance in exit food challenge improves Nearly half the patients could tolerate 2,000 mg in exit food challenge after 12 months of therapeutic dosing*** Peanut skin prick test wheel diameter decreases 10.8% of pa

  26. Slide 26: Immunologic Biomarkers Consistent With Other Effective Allergen Immunotherapies

    Immunologic Biomarkers, Efficacy, and Safety with AR101 Appear Consistent With Other Effective Allergen Immunotherapies Environmental SCIT* Venom SCIT** OIT with AR101*** Early rise in sIgE yes yes yes Late decline in sIgE yes yes yes Early rise in sIgG yes yes yes Late continued increase in IgG yes

  27. Slide 27: Preparing for Success at Launch

    Preparing for Success at Launch

  28. Slide 28: US Prevalence Data Indicate the Opportunity for Peanut Allergy Treatments

    US Prevalence Data Indicate the Opportunity to Address the Large Need for Peanut Allergy Treatments Source: Symphony Health Patient Claims (Jan 2011-Dec 2017) 1.25M Diagnosed and Managed 1.6M Prevalent Population (Ages 4-17) 83% peanut-allergic patients already diagnosed 18% 21% 42% 19% PA Only PA +

  29. Slide 29: High Level of Enthusiasm by Peanut Allergy Sufferers for an Approved OIT Solution

    Our Research Indicates a High Level of Enthusiasm by Peanut Allergy Sufferers for an Approved OIT Solution What Patients Want A treatment clinically proven to work to protect against reactions to accidental exposure Convenient, oral, once-daily dosing that doesn’t stigmatize them as peanut allergic

  30. Slide 30: Majority of Target Patients are Seen by Allergists Ready to Administer AR101

    Majority of Our Target Patients are Seen by Allergists Who Have Confirmed Readiness to Administer AR101 Source: Symphony Health Patient Claims (Jan 2011-Dec 2017) We’ve Profiled 4,400 of the ~5,000 US Allergists to Understand Their Practice Readiness to Administer AR101 Assessed Level of Practice Re

  31. Slide 31: Field Team Supports Allergists to Become Practice Ready

    Field Team Supports Allergists to Become ‘Practice Ready’ Team Sized to Provide Support to All Allergy Practices to Administer AR101 Supporting Allergists to Administer AR101 FDA approved product could reduce liability Implementation would be analogous to allergy shots Guidance can be provided regar

  32. Slide 32: Initial Conversations With U.S. Payers

    Initial Conversations With U.S. Payers Indicate Understanding of Need for Peanut Allergy Treatment Options Recognition of the high unmet medical need and corresponding potential level of demand from plan members Supportive of our focus on Allergist administration of AR101 Understanding of the longer

  33. Slide 33: AR101 Has the Potential to Deliver Clinical, Quality of Life, and Economic Values

    AR101 Has the Potential to Deliver Clinical, Quality of Life, and Economic Values Sustained Long-Term Desensitization Expected Improvement in Quality of Life Potential Healthcare Cost Savings PALISADE: 67.2% of AR101 patients able to tolerate 600mg (~2 peanuts) vs. 4% on placebo at the end of Year 1

  34. Slide 34: Cash Resources Fully Fund Commercialization of AR101 & Advance Pipeline

    Cash Resources1 Fully Fund Commercialization of AR101 & Advance Pipeline Development Complete financing Onboard Chief Commercial Officer BLA acceptance (Q1) ARTEMIS Phase 3 data (Q1) MAA Submission for AR101 (mid-19) Initiate AR201 Phase 2 for egg allergy (mid-19) Potential FDA Regulatory Actions fo

  35. Slide 35: Aimmune: Taking Off in 2019!

    Aimmune: Taking Off in 2019! Potential approval of first medicine for peanut allergy Very large commercial opportunity Excitement from allergists, patients and families Seasoned leadership with deep development, manufacturing and commercial experience Significant pipeline progress Well-funded and re

  36. Slide 36: Thank You

    Thank You mms ff Vs)

Aimmune Therapeutics — Investor Presentation (June 2019) on 6ix